Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 (COVID-19)

Perú. Ministerio de Salud. Instituto Nacional de Salud.
Lima; Instituto Nacional de Salud; 27 jul. 2020.
No convencional en Español | BRISA, LILACS | ID: biblio-1104225

Documentos relacionados

  1. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
  2. Potential therapeutic agents against COVID-19: What we know so far.
  3. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.
  4. Treatment of SARS-CoV-2: How far have we reached?
  5. High-cited favorable studies for COVID-19 treatments ineffective in large trials.
  6. Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
  7. Role of IFN-α in Rheumatoid Arthritis.
  8. Inhibiting cell-to-cell transmission to reach HDV cure: The importance of IFN-α.
  9. [A study of the clinical curative effect of nucleos(t)ide analogues treated to pegylated interferon-α add-on therapy in patients with chronic hepatitis B].
  10. [Precise immunological classification guidance for early initiation of antiviral therapy in patients with chronic HBV infection].